NEWS
View news from our Featured Companies.
Greenfire Resources Reports Year End 2024 Reserves, Fourth Quarter and Full Year 2024 Results, and Provides an Operational Update
Readers are advised to review the "Presentation of Reserves and Other Oil and Gas Information" and "Non-GAAP and Other Financial Measures" at the conclusion of this news release for information regarding the presentation of the reserves information, as well as certain...
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 13, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol “NAGE” Effective March 19, 2025
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq...
ARIANNE PHOSPHATE NAMES PIERRE FITZGIBBON AS A STRATEGIC ADVISOR TO THE COMPANY
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, March 13, 2025 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTCQX: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul...
SenesTech Announces Record Fourth Quarter and Full Year 2024 Financial Results with 70% Quarterly Revenue Growth; Gross Profit Margins of 61%; Reduction in Operating Expenses; and Dramatic Improvement in Adjusted EBITDA
Company announces new operating optimization initiatives to reduce expenses by approximately $2 million to accelerate path to profitability PHOENIX, March 12, 2025 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a pioneer in fertility control...
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 12, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),...
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and...
ChromaDex to Present at the 37th Annual Roth Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob...
LiqTech Expands Distribution Coverage in the Irish Swimming Pool Water Filtration System Market
BALLERUP, Denmark, March 11, 2025 -- LiqTech International, Inc. (NASDAQ: LIQT), a high-tech filtration technology company that manufactures and markets highly specialized filtration products and systems, today announced that it has entered a distribution and...
ARIANNE PHOSPHATE ENGAGES AUSTRALIAN-BASED INVESTOR RELATIONS FIRM
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, March 11, 2025 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSX VENTURE: DAN) (OTCQX: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à...
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections
Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company's...
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference. Iradimed's CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company...
SenesTech Announces Warrant Exercise for $1.1 Million in Gross Proceeds
PHOENIX, March 10, 2025 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a pioneer in fertility control solutions for managing rodent populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding...
SenesTech to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Wednesday, March 12, 2025
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, March 6, 2025 -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its fourth quarter and fiscal year 2024, ended December 31, 2024, after the...
Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board
GARDNER, Mass., March 04, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net...
InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024
Full Year 2024 vs. Full Year 2023: Record Net Revenues: $134.9 million, a 7% increase Patient Services Revenue: $80.4 million - Device Solutions Revenue: $54.5 million, increases of 5% and 11% Adjusted EBITDA (non-GAAP): $25.3 million, a 13% increase Record Operating...
A PARTNERSHIP INVOLVING ARIANNE PHOSPHATE RECEIVES $1.4 MILLION FOR WORK ASSOCIATED WITH THE LFP BATTERY
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, March 3, 2025 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSX VENTURE: DAN) (OTCQX: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul...
PolyPid to Participate in the 37th Annual ROTH Conference
PETACH TIKVA, Israel, March 03, 2025 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the 37th Annual ROTH Conference taking...
Mogo Announces Three-Year Extension to Credit Facility with Fortress Investment Group
Amendment Includes Lower Interest Rate Facility Expandable up to $100M VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), a digital wealth and payments business, today announced an amendment to its existing senior credit...
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GAITHERSBURG, Md., Feb. 26, 2025 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
PORTLAND, Maine, Feb. 25, 2025 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
SenesTech Expands its Rapidly Growing Global Footprint and Clears Major Regulatory Hurdle, Paving the Way for Use in Australia and New Zealand
SenesTech and Distribution Partner to Bring Evolve™ to New Zealand's Predator Free 2050 Initiative PHOENIX, Feb. 25, 2025 -- SenesTech, Inc. (Nasdaq: SNES), a pioneer in fertility control solutions for managing rodent populations, is pleased to announce a...